Results 81 to 90 of about 36,964 (190)
Антибиотики и Химиотерапия, 2020 Addition of perfluorodecalin with gas-transporting function to the liquid medium during submerged cultivation of actinomycetes of the genus Streptomyces resulted in higher intensity and level of the biomass synthesis and increased production of ...
V. M. Bakulin +5 more
doaj
HemaSphere, Volume 10, Issue 8, August 2026.Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li +36 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background and Aims Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent whose clinical utility is significantly constrained by severe side effects, most notably DOX‐induced cardiotoxicity (DIC). Pathophysiological mechanisms of DIC include oxidative stress, mitochondrial dysfunction, programmed cell death, and inflammation ...
Ali Mirzaei +8 more
wiley +1 more source
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a high risk of relapse. Leukemia cutis is characterized by the presence of neoplastic leukocytes infiltrating the skin. Here, we present a previously treated AML patient who relapsed with isolated leukemia cutis without bone marrow involvement. Fluorescence in
Bana Antonios +9 more
wiley +1 more source
Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?
American Journal of Hematology, Volume 101, Issue 8, Page 1783-1789, August 2026.
Sudhir Tauro, Ayalew Tefferi
wiley +1 more source
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Introduction Sinusoidal obstruction syndrome, also known as veno‐occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin‐based antibody‐drug conjugate. Case Presentation We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without ...
Emi Yokoyama +10 more
wiley +1 more source
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT CPX‐351 is associated with reduced non‐hematologic toxicity, but its cardiac safety is not well defined. We prospectively assessed ejection fraction (EF) and global longitudinal strain (GLS) in younger adults with AML treated with a single CPX‐351‐based induction. Median changes were mild and comparable to standard “7 + 3”.
Chezi Ganzel +7 more
wiley +1 more source
British Journal of Haematology, Volume 209, Issue 2, Page 589-600, August 2026.Summary Central nervous system (CNS) involvement and relapse remains a clinical challenge in the management of acute lymphoblastic leukaemia (ALL), and studies among adult ALL patients are scarce. We identified all adult ALL patients in Sweden between 2007 and 2022 (n = 838) from the population‐based ALL register and evaluated factors associated with ...
Erik Boberg +7 more
wiley +1 more source
British Journal of Pharmacology, Volume 183, Issue 16, Page 4663-4674, August 2026.Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski +13 more
wiley +1 more source